

# Mass spectrometry-based ligand binding assays on adenosine A<sub>1</sub> and A<sub>2A</sub> receptors

A. Massink<sup>1</sup> · M. Holzheimer<sup>1</sup> · A. Hölscher<sup>1</sup> · J. Louvel<sup>1</sup> · D. Guo<sup>1</sup> · G. Spijksma<sup>2</sup> · T. Hankemeier<sup>2</sup> · A. P. IJzerman<sup>1,3</sup>

Received: 2 September 2015 / Accepted: 2 October 2015 / Published online: 19 October 2015  
© The Author(s) 2015. This article is published with open access at Springerlink.com

**Abstract** Conventional methods to measure ligand-receptor binding parameters typically require radiolabeled ligands as probes. Despite the robustness of radioligand binding assays, they carry inherent disadvantages in terms of safety precautions, expensive synthesis, special lab requirements, and waste disposal. Mass spectrometry (MS) is a method that can selectively detect ligands without the need of a label. The sensitivity of MS equipment increases progressively, and currently, it is possible to detect low ligand quantities that are usually found in ligand binding assays. We developed a label-free MS ligand binding (MS binding) assay on the adenosine A<sub>1</sub> and A<sub>2A</sub> receptors (A<sub>1</sub>AR and A<sub>2A</sub>AR), which are well-characterized members of the class A G protein-coupled receptor (GPCR) family. Radioligand binding assays for both receptors are well established, and ample data is available to compare and evaluate the performance of an MS binding assay. 1,3-Dipropyl-8-cyclopentyl-xanthine (DPCPX) and 4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-*a*]-[1,3,5]triazin-5-yl)amino)ethyl)phenol (ZM-241,385) are high-affinity ligands selective for the A<sub>1</sub>AR and A<sub>2A</sub>AR, respectively. To proof the feasibility of MS binding on the A<sub>1</sub>AR and

A<sub>2A</sub>AR, we first developed an MS detection method for unlabeled DPCPX and ZM-241,385. To serve as internal standards, both compounds were also deuterium-labeled. Subsequently, we investigated whether the two unlabeled compounds could substitute for their radiolabeled counterparts as marker ligands in binding experiments, including saturation, displacement, dissociation, and competition association assays. Furthermore, we investigated the accuracy of these assays if the use of internal standards was excluded. The results demonstrate the feasibility of the MS binding assay, even in the absence of a deuterium-labeled internal standard, and provide great promise for the further development of label-free assays based on MS for other GPCRs.

**Keywords** MS binding · Mass spectrometry · Radioligand binding · Adenosine receptor · Deuteration

## Introduction

Conventional methods to measure ligand-receptor binding parameters typically require labeled probes such as radiolabeled [1] or fluorescently labeled ligands [2]. Despite the robustness of radioligand binding assays, they carry inherent disadvantages in terms of safety precautions, expensive synthesis, special lab requirements, and waste disposal. Alternatively, the addition of fluorescent moieties holds a substantial risk of affecting the pharmacological properties of a ligand; moreover, in many instances, it is also required to engineer the receptor protein, in particular for fluorescence resonance energy transfer assays [3].

The development of the mass spectrometry (MS) binding assay by the group of Wanner permits to measure binding of an unlabeled ligand to its target [4]. Instead of the radiolabeled ligand in radioligand binding assays, an unlabeled marker

**Electronic supplementary material** The online version of this article (doi:10.1007/s11302-015-9477-0) contains supplementary material, which is available to authorized users.

✉ A. P. IJzerman  
ijzerman@lacdr.leidenuniv.nl

<sup>1</sup> Division of Medicinal Chemistry, LACDR, Leiden University, Leiden, The Netherlands

<sup>2</sup> Division of Analytical Biosciences, LACDR, Leiden University, Leiden, The Netherlands

<sup>3</sup> Leiden Academic Centre for Drug Research, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands

ligand is employed in MS binding assays. The amount of marker ligand bound to the target receptor is detected by mass spectrometry. As the mass of the molecule itself is detected, a label is not necessary. However, the marker ligand still has to fulfill the same requirements as radioligands: high affinity and selectivity for the target and low non-specific binding [5]. Therefore, it is practical to choose a ligand for MS binding applications that has already been validated as a good radioligand. This also ensures a straightforward validation of an MS binding assay by comparing it to existing radioligand binding assays.

In this study, we developed an MS binding assay for the adenosine A<sub>1</sub> (hA<sub>1</sub>AR) and adenosine A<sub>2A</sub> receptors (hA<sub>2A</sub>AR). The particular robustness and abundance of published results of radioligand binding assays on the hA<sub>1</sub>AR and hA<sub>2A</sub>AR make these receptors good candidates for development of an MS binding assay [6]. The adenosine receptors are members of the class A of G protein-coupled receptors (GPCRs). Both receptors are important in physiology. The hA<sub>1</sub>AR has been related to sleep regulation, epilepsy, and asthma. The hA<sub>2A</sub>AR is implicated in neurodegeneration, inflammatory diseases, and cancer pathogenesis. Both receptors are involved in cardiovascular physiology [6, 7]. As marker ligands for the MS binding assay, we chose 1,3-dipropyl-8-cyclopentyl-xanthine (DPCPX) for the hA<sub>1</sub>AR and 4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-*a*]-[1,3,5]triazin-5-yl)amino)ethyl)phenol (ZM-241,385) for the hA<sub>2A</sub>AR. These ligands are well-established radioligands for their respective targets and hence a logical choice to serve as marker ligands in MS binding assays [8, 9].

The development of liquid chromatography-MS (LC-MS) detection methods for non-labeled DPCPX and ZM-241,385 as marker ligands involved the following steps. Firstly, deuterated isotopologues of the marker ligands were synthesized to serve as internal standards for increased accuracy of the MS detection. In MS detection methods, it is common to add a fixed amount of an internal standard to each sample to compensate for ion suppression, sample evaporation, and instrumental drift [10]. Technically, the use of deuterium-labeled internal standards makes the MS binding assay a labeled assay, even if the marker ligand that binds to the target is unlabeled itself. Therefore, we also investigated whether the results of the MS binding assays were accurate in the absence of an internal standard. Secondly, a fast LC method was developed to separate the marker ligands from cell membrane contents in the sample. The duration of the LC separation is the limiting step for the throughput of the method so this is preferably fast, i.e., within 1 min. Thirdly, for MS detection, a triple quadrupole MS (TQMS) was employed, which has the required sensitivity to measure typical bound ligand quantities of ligand binding assays, in the pM range. In a TQMS, the parent ions with the mass of the molecule of interest are filtered by the

first quadrupole, which are then fragmented in the second quadrupole. The fragmentation results in daughter ions that are analyzed by the third quadrupole. This setup ensures a high selectivity and sensitivity for the detection of a molecule of interest [11].

After establishing the LC-MS methods for detection of the marker ligands, the MS binding assays were performed with and without deuterium-labeled internal standard, and analogous to radioligand binding assays. Saturation, association, and dissociation assays were performed to determine the affinity and kinetic rates of the marker ligands DPCPX for the hA<sub>1</sub>AR and ZM-241,385 for the hA<sub>2A</sub>AR. Then displacement and competition association assays were performed to determine the affinity and kinetic rates of ligands competing with the marker ligands. The ensuing results were compared to and validated with reference radioligand binding data.

## Materials and methods

### Materials

Adenosine deaminase (ADA) was purchased from Boehringer Mannheim (Mannheim, Germany). DPCPX, 5'-*N*-ethylcarboxamidoadenosine (NECA), and bovine serum albumin (BSA) were purchased from Sigma (St. Louis, MO, USA). ZM-241,385 was purchased from Ascent Scientific (Bristol, UK). *N*<sup>6</sup>-Cyclopentyladenosine (CPA) was purchased from Abcam Biochemicals (Cambridge, UK). 6-(2,2-Diphenylethylamino)-9-((2*R*,3*R*,4*S*,5*S*)-5-(ethylcarbonyl)-3,4-dihydroxytetrahydrofuran-2-yl)-*N*-(2-(3-(1-(pyridin-2-yl)piperidin-4-yl)ureido)ethyl)-9*H*-purine-2-carboxamide (UK-432,097) was obtained as a gift through Pfizer's Compound Transfer Program. 3-(3-Hydroxypropyl)-7-methyl-1-propargyl-8-(*m*-methoxystryryl)xanthine (MSX-2) [12] was a gift from Prof. C. E. Müller (Bonn University, Germany). 8-Cyclopentyltheophylline (8-CPT) was purchased from Research Biochemicals Inc. (Natick, MA, USA). 8-Cyclopentyl-3-(3-((4-(fluorosulfonylbenzoyl)oxy)propyl)-1-propylxanthine (FSCPX) [13] and *N*<sup>5</sup>-(2-(4-(2,4-difluorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-*a*][1,3,5]triazine-5,7-diamine (LUF6632) [14] were synthesized in-house. Bicinchoninic acid (BCA) and BCA protein assay reagent were obtained from Pierce Chemical Company (Rockford, IL, USA). CHO cells stably expressing the hA<sub>1</sub>AR (CHO-hA<sub>1</sub>AR) were a gift from Prof. S. Hill (University of Nottingham, UK). HEK293 cells stably expressing the hA<sub>2A</sub>AR (HEK293-hA<sub>2A</sub>AR) were a gift from Dr. J. Wang (Biogen/IDEC, Cambridge, MA, USA). All other chemicals were of analytical grade and obtained from standard commercial sources.

## General synthesis procedures

Demineralised water is simply referred to as H<sub>2</sub>O, as was used in all cases unless stated otherwise. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker AV 400 liquid spectrometer (<sup>1</sup>H NMR, 400 MHz; <sup>13</sup>C NMR, 100 MHz) at ambient temperature. Chemical shifts are reported in parts per million (ppm), are designated by  $\delta$ , and are downfield to the internal standard tetramethylsilane (TMS) in CDCl<sub>3</sub>. Coupling constants are reported in Hertz and are designated as *J*. Analytical purity of the final compounds was determined by high pressure liquid chromatography (HPLC) with a Phenomenex Gemini 3- $\mu$ m C18 110A column (50 $\times$ 4.6 mm, 3  $\mu$ m), measuring UV absorbance at 254 nm. Sample preparation and HPLC method were—unless stated otherwise—as follows: 0.3–0.8 mg of compound was dissolved in 1 ml of a 1:1:1 mixture of CH<sub>3</sub>CN/H<sub>2</sub>O/tBuOH and eluted from the column within 15 min, with a three-component system of H<sub>2</sub>O/CH<sub>3</sub>CN/1 % TFA in H<sub>2</sub>O, decreasing polarity of the solvent mixture in time from 80:10:10 to 0:90:10. All compounds showed a single peak at the designated retention time and were at least 95 % pure. The synthesized compounds were identified by LC-MS analysis using a Thermo Finnigan Surveyor-LCQ Advantage Max LC-MS system and a Gemini C18 Phenomenex column (50 $\times$ 4.6 mm, 3  $\mu$ m). The sample preparation was the same as for HPLC analysis. The elution method was set up as follows: 1–4 min isocratic system of H<sub>2</sub>O/CH<sub>3</sub>CN/1 % TFA in H<sub>2</sub>O, 80:10:10, from the fourth minute, a gradient was applied from 80:10:10 to 0:90:10 within 9 min, followed by 1 min of equilibration at 0:90:10 and 1 min at 80:10:10. Thin-layer chromatography (TLC) was routinely performed to monitor the progress of reactions, using aluminum-coated Merck silica gel F254 plates. Purification by column chromatography was achieved by use of Grace Davison Davisil silica column material (LC60A 30–200  $\mu$ m). Solutions were concentrated using a Heidolph laborota W8 2000 efficient rotary evaporation apparatus and by a high vacuum on a Binder APT line Vacuum Drying Oven.

### Preparation of 8-cyclopentyl-1,3-bis(propyl-2,3-d<sub>2</sub>)-3,9-dihydro-1*H*-purine-2,6-dione 2 ([<sup>2</sup>H<sub>4</sub>]DPCPX)

Synthesis steps to arrive to compound 1 (SI Scheme 3) were performed as previously described [15–17]. 1,3-Diallyl-8-cyclopentyl-3,9-dihydro-1*H*-purine-2,6-dione 1 (1 mmol, 300 mg) and NaBD<sub>4</sub> (4 mmol, 167 mg) were placed in a flask. The flask was flame-dried under vacuum to remove traces of water and then purged with N<sub>2</sub> gas. Dry THF (10 ml) was added. RhCl(PPh<sub>3</sub>)<sub>3</sub> was placed in another flame-dried flask under N<sub>2</sub>-atmosphere and suspended in dry THF (1 ml). The flask containing 1 was heated to 60 °C, and the reaction was started upon addition of the catalyst suspension, followed by D<sub>2</sub>O (2 mmol, 0.04 ml). The mixture was stirred at 60 °C for

19 h. The reaction mixture was then poured into EtOAc and washed with brine (3 $\times$ ). The organic layer was dried over MgSO<sub>4</sub> and concentrated. The crude product was purified by column chromatography (PET/EtOAc 5/1  $\rightarrow$  4/1  $\rightarrow$  3/2). The product 2 was obtained as white solid (46 %, 0.46 mmol, 141 mg). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  11.92 (br s, 1H), 4.11–4.06 (m, 2H), 4.03–3.97 (m, 2H), 3.30–3.21 (m, 1H), 2.18–2.11 (m, 2H), 1.98–1.68 (m, 8H), 0.99–0.94 (m, 4H) ppm. MS: [M+H]<sup>+</sup> calculated 309.22, found 309.20. HPLC purity 97 % (*t*<sub>R</sub> 9.587 min, mobile phase 15–65 % MeCN/H<sub>2</sub>O+TFA).

### Preparation of 4-(2-((7-amino-2-(furan-2-yl)-1,3a-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino)ethyl)phen-2,3,5,6-d<sub>4</sub>-ol 5 ([<sup>2</sup>H<sub>4</sub>]ZM-241,385)

Synthesis steps to arrive to compounds 3 and 4 (SI Scheme 4) were performed as previously described [18–20]. [<sup>2</sup>H<sub>4</sub>]Tyramine 4 (0.37 mmol, 53 mg) was suspended in 4 ml MeCN, and Et<sub>3</sub>N (0.14 ml) and 2-(furan-2-yl)-5-(methylsulfonyl)-1,3a-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine 3 (0.34 mmol, 95 mg) were added. The mixture was stirred for 3 h at 70 °C under microwave irradiation. The solvent was evaporated, and the crude material was adsorbed onto silica and purified by column chromatography (EtOAc/MeOH 99/1) and subsequent PTLC (EtOAc/MeOH 99.5/0.5) to give the product 5 as an off-white solid (45 %, 0.15 mmol, 52 mg). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  9.17 (s, 1H), 8.13 (br s, 2H), 7.86 (s, 1H), 7.53–7.52 and 7.50–7.42 (m, 1H, rotamers), 7.05 (d, *J*=3.2, 1H), 6.67 (m, 1H), 3.43–3.40 (m, 2H), 2.74–2.71 (m, 2H) ppm. MS: [M+H]<sup>+</sup> calculated 342.16, found 342.7. HPLC purity 95 % (*t*<sub>R</sub> 6.408 min, mobile phase 10–90 % MeCN/H<sub>2</sub>O+TFA).

## Cell culture

CHO-hA<sub>1</sub>AR cells were grown in Ham's F12 medium containing 10 % normal adult bovine serum, 100  $\mu$ g/ml streptomycin, 100 IU/ml penicillin, and 400  $\mu$ g/ml G418, at 37 °C in 5 % CO<sub>2</sub>. HEK293-hA<sub>2A</sub>AR cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % newborn calf serum, 50  $\mu$ g/ml streptomycin, 50 IU/ml penicillin, and 200  $\mu$ g/ml G418, at 37 °C and 7 % CO<sub>2</sub>. Cells were subcultured twice a week on 10-cm  $\phi$  plates at a ratio of 1:20 for CHO hA<sub>1</sub>R cells and 1:8 for HEK293 hA<sub>2A</sub>AR cells.

## Membrane preparation

CHO-hA<sub>1</sub>AR and HEK293-hA<sub>2A</sub>AR cells were grown as described above. Membranes were prepared as follows. Cells were detached from plates grown to confluency by scraping them into 5 ml PBS, collected and centrifuged at 700g (3000 rpm) for 5 min. Pellets derived from 20 plates (10 cm

**Table 1** Mass of detected parent and daughter ions. Parent ions were fragmented to daughter ions with different optimal collision energies for each daughter ion


	Parent ion	Daughter ion	Collision energy (V)
DPCPX	305.00	178.15	35
		204.10	36
		221.15	27
		263.10	23
[ <sup>2</sup> H]DPCPX	309.00	178.10	36
		204.05	35
		221.05	29
		265.00	23
ZM-241,385	338.10	77.05	55
		121.05	29
		176.10	30
		218.10	24
		263.10	23
[ <sup>2</sup> H]ZM-241,385	342.10	80.05	65
		125.10	30
		176.05	32
		218.05	26
		263.10	23

ø) were pooled and resuspended in 16 ml of ice-cold assay buffer (50 mM Tris-HCl, 5 mM MgCl<sub>2</sub>, pH 7.4). An Ultra-Turrax was used to homogenize the cell suspension. Membranes and the cytosolic fraction were separated by centrifugation at 100,000g (31,000 rpm) in a Beckman Optima LE-80K ultracentrifuge at 4 °C for 20 min. The pellet was resuspended in 8 ml of Tris buffer and the homogenization and centrifugation step was repeated. Assay buffer (4 ml) was used to resuspend the pellet, and adenosine deaminase (ADA) was added (0.8 IU/ml) to break down endogenous adenosine. Membranes were stored in 250-μl aliquots at -80 °C. Membrane protein concentrations were measured using the BCA (bicinchoninic acid) method [21].

### Radioligand binding assays

The reference radioligand binding data were published before by our lab or were acquired as described before [22, 23].

**Scheme 1** Synthesis of [<sup>2</sup>H<sub>4</sub>]DPCPX (2). Reagents and conditions: Rh(PPh<sub>3</sub>)<sub>3</sub>Cl, NaBD<sub>4</sub>, D<sub>2</sub>O, dry THF, 60 °C, 3.5 h



### Membrane harvesting procedure MS binding assays

One hundred-microliter membrane aliquots containing 5 μg (CHO-hA<sub>1</sub>AR) or 22 μg (HEK293-hA<sub>2A</sub>AR) of protein in assay buffer were harvested by rapid vacuum filtration through 1-μm glass fiber AcroPrep Advance 96 filter plates (Pall Corporation, Ann Arbor, MI, USA) using an extraction plate manifold (Waters, Milford, MA, USA) and a 12-channel electronic pipette (Gilson, Middleton, WI, USA). Filters were subsequently washed three times with ice-cold assay buffer and dried for 1 h at 55 °C. It was essential that the filter plates were completely dry before continuing with ligand elution as described below in “Sample elution.”


### MS binding saturation assays

Membrane aliquots containing 5 μg (CHO-hA<sub>1</sub>AR) or 22 μg (HEK293-hA<sub>2A</sub>AR) of protein were incubated in a total volume of 100 μl of assay buffer at 25 °C for 1 h (hA<sub>1</sub>AR) or at 4 °C for 3 h (hA<sub>2A</sub>AR). Total binding was determined at increasing concentrations of marker ligand DPCPX (0.08–40 nM on hA<sub>1</sub>AR) or marker ligand ZM-241,385 (0.05–15 nM on hA<sub>2A</sub>AR). Dilutions were prepared with a HP D300 Digital Dispenser (Tecan Group, Männerdorf, Swiss) from DMSO stocks. Non-specific binding in presence of 100 μM CPA (hA<sub>1</sub>AR) or 100 μM NECA (hA<sub>2A</sub>AR) was determined at three concentrations of marker ligand and analyzed by linear regression. Incubations were terminated and samples were harvested as described under “Membrane harvesting procedure MS binding assays.”

### MS binding displacement assays

Ligand displacement experiments were performed using nine concentrations of competing ligand. For the hA<sub>1</sub>AR, the competing ligands used were CPA, 8-CPT, ZM-241,385, and NECA, while for the hA<sub>2A</sub>AR, they were UK-432,097, MSX-2, DPCPX, and NECA. As marker ligand DPCPX was used for the hA<sub>1</sub>AR at a concentration of 6 nM, and ZM-241,385 for the hA<sub>2A</sub>AR at a concentration of 3 nM. Non-specific binding was determined in the presence of

**Scheme 2** Synthesis of [ $^2\text{H}_4$ ]ZM-241,385 (5). Reagents and conditions:  $\text{Et}_3\text{N}$ , MeCN, MW, 70 °C, 3 h



100  $\mu\text{M}$  CPA for the  $\text{hA}_1\text{AR}$  and 100  $\mu\text{M}$  NECA for the  $\text{hA}_{2A}\text{AR}$ . Incubations were terminated as described under “Membrane harvesting procedure MS binding assays.”

### MS binding association assays

Membrane aliquots containing 5  $\mu\text{g}/100 \mu\text{l}$  (CHO- $\text{hA}_1\text{AR}$ ) or 22  $\mu\text{g}/100 \mu\text{l}$  (HEK293- $\text{hA}_{2A}\text{AR}$ ) of protein were incubated in a total volume of 2400  $\mu\text{l}$  of assay buffer at 25 °C with 6 nM DPCPX for  $\text{hA}_1\text{AR}$  or at 4 °C with 3 nM ZM-241,385 for  $\text{hA}_{2A}\text{AR}$ . At each time point, 100  $\mu\text{l}$  from the reaction mix was harvested as described under “Membrane harvesting procedure MS binding assays” to determine the amount of marker ligand bound to the receptor. Non-specific binding was determined as described under “MS binding displacement assays.”

### MS binding dissociation assays

Membrane aliquots containing 5  $\mu\text{g}/100 \mu\text{l}$  (CHO- $\text{hA}_1\text{AR}$ ) or 22  $\mu\text{g}/100 \mu\text{l}$  (HEK293- $\text{hA}_{2A}\text{AR}$ ) of protein were incubated in a total volume of 2400  $\mu\text{l}$  of assay buffer at 25 °C with 6 nM DPCPX ( $\text{hA}_1\text{AR}$ ) or at 4 °C with 3 nM ZM-241,385 ( $\text{hA}_{2A}\text{AR}$ ). The reaction mixes were allowed to reach equilibrium for 1 h before starting the dissociation by adding 100  $\mu\text{M}$  CPA ( $\text{hA}_1\text{AR}$ ) or NECA ( $\text{hA}_{2A}\text{AR}$ ). At each time point,


100  $\mu\text{l}$  from the reaction mix was harvested as described under “Membrane harvesting procedure MS binding assays” to determine the amount of marker ligand still bound to the receptor. Non-specific binding was determined as described under “MS binding displacement assays.”

### MS binding competition association assays

Membrane aliquots containing 5  $\mu\text{g}/100 \mu\text{l}$  (CHO- $\text{hA}_1\text{AR}$ ) or 22  $\mu\text{g}/100 \mu\text{l}$  (HEK293- $\text{hA}_{2A}\text{AR}$ ) of protein were incubated in a total volume of 2400  $\mu\text{l}$  of assay buffer at 25 °C with 6 nM DPCPX in the absence or presence of 250 nM 8-CPT or 250 nM FSCPX ( $\text{hA}_1\text{AR}$ ) or at 4 °C with 3 nM ZM-241,385 in the absence or presence of 90 nM MSX-2 or 15 nM LUF6632 ( $\text{hA}_{2A}\text{AR}$ ). At each time point, 100  $\mu\text{l}$  from the reaction mix was harvested as described under “Membrane harvesting procedure MS binding assays” to determine the amount of marker ligand bound to the receptor. Non-specific binding was determined as described under “MS binding displacement assays.”

### Sample elution

The ligand was eluted from the ligand-receptor complex on the dried filter plates over which MS binding samples were




**Fig. 1** Standard curve of increasing concentrations of marker ligands **a** DPCPX with 2 nM [ $^2\text{H}$ ]DPCPX and **b** ZM-241,385 with 2 nM [ $^2\text{H}$ ]ZM-241,385 in matrix membrane samples. On the x-axis is plotted the

concentration of marker ligand. On the y-axis is plotted the marker area TIC divided by IS area TIC (M/IS). Data shown is the average of M/IS values  $\pm$  SEM from four runs in hexaplicate

harvested. One hundred microliters of eluent (50 % methanol, 50 % ammonium formate buffer [final concentration 5 mM] at pH 7, spiked with 2 nM [ $^2\text{H}$ ]DPCPX or [ $^2\text{H}$ ]ZM-241,385 as internal standard, all HPLC grade) was applied to the filter plates which were then centrifuged for 1 min at 800g (2000 rpm) in a 5810 plate centrifuge (Eppendorf, Hamburg, Germany), while filter eluates were collected in 1.1-ml polystyrene deep 96-well plates

(BrandTech Scientific, Essex, CT, USA). This procedure was performed twice resulting in a total of 200  $\mu\text{l}$  eluate for each sample. For standard curve samples, the same procedure was followed but for the presence of increasing concentrations (1–100 pM) of DPCPX or ZM-241,385 in the eluent. After elution, 96-deep-well plates were sealed with rapid easy pierce film (Nacalai, San Diego, CA, USA) and stored at  $-20\text{ }^\circ\text{C}$  before LC-MS-MS quantification.

**Fig. 2** Typical chromatograms of **a** non-specific binding of DPCPX (31 pM), **b** total binding of DPCPX (242 pM), and **c** [ $^2\text{H}$ ]DPCPX (2 nM) in eluate containing hA<sub>1</sub>AR membrane matrix, and of **d** non-specific binding of ZM-241,385 (42 pM), **e** total binding of ZM-241,385 (289 pM), and **f** [ $^2\text{H}$ ]ZM-241,385 (2 nM) in eluate containing hA<sub>2A</sub>AR membrane matrix. The red lines delineate the area of peak integration




## LC-MS-MS quantification


All solvents used were of LC-MS grade or better. The LC-ESI-MS-MS setup consisted of a Nexera X2 UHPLC (Shimadzu, Kyoto, Japan; degassing unit: 20A3R, autosampler: 30AC, column oven: 30AD) and a LCM-8050 triple quadrupole mass spectrometer (Shimadzu, Kyoto, Japan) with an electrospray ionization source (ESI) in positive mode. Chromatographic separation was performed on an Acquity UPLC BEH C18 column (1×50 mm, 1.7 μm; Waters, Milford, MA, USA) with a VanGuard precolumn of the same type (2.1×5 mm). The column oven was set at 40 °C. Mobile phases consisted of acetonitrile, methanol, and ammonium formate buffer (final concentration 5 mM) at pH 7, all of LC-MS grade or better, in respective volume fractions of 5:5:90 (solvent A) and 45:45:10 (solvent B). An isocratic mobile phase flow of 0.2 ml/min was applied consisting of solvents A:B (10:90 for the DPCPX and 35:65 for the ZM-241,385 quantification methods), which resulted in column pressures of 400 and 500 bar, respectively. The sample eluate injection volume was 20 μl and run time was 1 min. Source and fragmentation parameters were acquired by the Shimadzu optimization for method function (Table 1). For each ligand, the parent and four daughter ions were detected by multiple reaction monitoring (MRM) in positive mode. Additional MS settings were as follows: ESI interface temperature 300 °C; DL temperature 250 °C; heat block temperature 400 °C; ion spray voltage 4 kV; heating and drying gas flows 10 l/min; nebulizing gas flow 3 l/min.

## Data analysis

Shimadzu LabSolutions software (Shimadzu, Kyoto, Japan) was used to analyze resulting chromatogram peaks. The peak area of the total ion count (TIC) of the daughter ions was calculated at the expected retention times, resulting in marker and internal standard peak area. To compensate for eluent evaporation and signal suppression by matrix effects from the membrane sample, marker peak area was divided by internal standard peak area (M/IS). Lower limit of quantitation (LLOQ) values of each marker ligand were defined as the lowest concentration in membrane matrix where signal to noise ratio was higher than 5, the standard deviation within and between runs in hexuplicate was lower than 20 % (and for all higher concentrations lower than 15 %), and calculation of concentration by a function derived from  $1/x^2$  linear regression deviated from nominal values less than 20 %. M/IS values were converted to concentration of marker ligand in pM using the function established by  $1/x^2$  linear regression on the 10–100-pM standard curve results. The resulting MS binding data was then analyzed with GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA). Marker ligand displacement curves were fitted to one- and two-state site binding models.  $k_{on}$  and  $k_{off}$  values of the marker ligands DPCPX and ZM-241,385 were derived by fitting one-phase association and dissociation models. Association and dissociation rates for the competing ligands were calculated by fitting the data to the competition association model using “kinetics of competitive binding” [24]. Log-transformed  $K_i$ ,  $K_D$ ,  $k_{on}$ , and  $k_{off}$  values from MS binding and radioligand binding assays

**Fig. 3** Saturation of DPCPX binding to  $hA_1AR$  (a, b) and ZM-241,385 binding to  $hA_{2A}AR$  (c, d). Increasing concentrations of marker ligands were incubated with the respective membranes. Data shown without (a, c) and with (b, d) non-specific binding values subtracted. Graphs show mean values of one representative MS binding saturation experiment performed in duplicate





**Fig. 4** Displacement of DPCPX binding to hA<sub>1</sub>AR by CPA, 8-CPT, ZM-241,385, or NECA (**a**) and of ZM-241,385 binding to hA<sub>2A</sub>AR by UK-432,097, MSX-2, DPCPX, or NECA (**b**). Non-specific binding is plotted

at  $-3$  on the  $x$ -axis. Graphs show mean values of one representative MS binding displacement experiment performed in duplicate

were plotted, and a linear regression analysis was applied. A similar correlation plot was prepared with values from MS binding assays based on solely marker peak area values instead of M/IS.

## Results

### Synthesis of [<sup>2</sup>H<sub>4</sub>]DPCPX 2


[<sup>2</sup>H<sub>4</sub>]DPCPX 2 was prepared according to the synthetic route shown in Scheme 1 and SI Scheme 3 and was adopted from previously described syntheses of non-deuterated DPCPX [15–17]. After the synthesis steps to arrive at compound 1 (SI Scheme 3), the allylic double bonds of the DPCPX precursor 1 were reductively deuterated in the presence of Wilkinson's catalyst with NaBD<sub>4</sub> as a deuterium source generating deuterium gas in situ upon addition of D<sub>2</sub>O [25]. The

mass spectrum showed a mass range for the (M+H<sup>+</sup>) species from 305.20 ([<sup>2</sup>H<sub>0</sub>] isotopologue) to 313.27 ([<sup>2</sup>H<sub>8</sub>] isotopologue) in a Gaussian distribution with the desired [<sup>2</sup>H<sub>4</sub>]DPCPX 2 as most abundant isotopologue generating the main mass peak at 309.33.

### Synthesis of [<sup>2</sup>H<sub>4</sub>]ZM-241,385 5

[<sup>2</sup>H<sub>4</sub>]ZM-241,385 5 was prepared according to the synthetic route shown in Scheme 2 and SI Scheme 4 and was adopted from previously described syntheses of non-deuterated ZM-241,385 [18–20]. After the synthesis steps to arrive at compounds 3 and 4 (SI Scheme 4), reaction of the [<sup>2</sup>H<sub>4</sub>]tyramine 4 with methylsulfone compound 3 yielded the final product [<sup>2</sup>H<sub>4</sub>]ZM-241,385 5 [18]. MS analysis showed a mass of 342.7 (M+H<sup>+</sup>) and confirmed the incorporation of four deuterium atoms in the final product.

**Fig. 5** Association (**a, c**) and dissociation (**b, d**) of DPCPX on hA<sub>1</sub>AR (**a, b**) and ZM-241,385 on hA<sub>2A</sub>AR (**c, d**). Graphs show mean values of one representative MS binding association or dissociation experiment performed in duplicate





## LC-MS results of DPCPX, [ $^2\text{H}$ ]DPCPX, ZM-241,385, and [ $^2\text{H}$ ]ZM-241,385

Standard curves were made for the quantitation of DPCPX and ZM-241,385 concentrations in biological membrane matrix by LC-MS (Fig. 1). Membrane samples without addition of ligand were filtered, and the applied eluent contained increasing concentrations of DPCPX and ZM-241,385, in addition to 2 nM of their deuterated counterparts. This method ensured standard curves in presence of the same biological matrix as for the quantitated MS binding samples. The LLOQ values derived from the standard curves were 20 pM for DPCPX and 40 pM for ZM-241,385 and were below non-specific binding concentrations found in MS binding assays for DPCPX (31 pM) and ZM-241,385 (42 pM). The linear regression equations to calculate marker ligand concentrations from the M/IS values derived from the standard curves were  $y=0.00341x+0.117$  with  $R^2=0.988$  for DPCPX and  $y=0.00130x+0.0225$  with  $R^2=0.987$  for ZM-241,385.


## Binding assays

DPCPX and ZM-241,385 were used as marker ligands for the MS binding assays. These marker ligands are also available as well-established tritium-labeled radioligands with high affinity for respectively the  $\text{hA}_1\text{AR}$  and  $\text{hA}_{2A}\text{AR}$ , which made it possible to validate the MS binding assays. For the displacement assays, the competing ligands on the  $\text{hA}_1\text{AR}$  were CPA (selective agonist), 8-CPT (selective antagonist), ZM-241,385 ( $\text{hA}_{2A}\text{AR}$ -selective antagonist), and NECA (non-selective agonist), and on the  $\text{hA}_{2A}\text{AR}$ , they were UK-432,097 (selective agonist), MSX-2 (selective antagonist), DPCPX ( $\text{hA}_1\text{AR}$ -selective antagonist), and NECA. For the competition association assays, the competing ligands on the  $\text{hA}_1\text{AR}$  were 8-CPT (fast dissociation) and FSCPX (irreversibly binding to  $\text{hA}_1\text{AR}$  resulting in an apparent slow dissociation), and on the  $\text{hA}_{2A}\text{AR}$ , they were MSX-2 (fast dissociation) and LUF6632 (slow dissociation). Marker ligand concentrations that were found in the eluates of the MS binding assays ranged from 31 to 242 pM for DPCPX and 42 to 289 pM for ZM-241,385 (Fig. 2). The MS binding data in Figs. 3, 4, 5, and 6 and

Tables 2, 3, 4, 5, and 6 is based on data with deuterium-labeled internal standard compensation of the marker ligand peak area (M/IS), except when stated otherwise in Tables 5 and 6. In Fig. 7, both M/IS-based and marker peak area-based (without internal standard compensation and thus completely unlabeled) data are compared with radioligand binding data.

For the validation of MS binding assays, radioligand binding data that was published previously by our group was used. In the case that no in-house radioligand binding data was available, the concerning assays were performed following previously established protocols [22, 23]. Radioligand binding data for the marker ligands DPCPX and ZM-241,385 on their respective targets from saturation, association, and dissociation assays was published previously (Table 2). Displacement and competition association radioligand binding data of the competing ligands NECA (displacement on  $\text{hA}_1\text{AR}$  and  $\text{hA}_{2A}\text{AR}$ ), UK-432,097 (displacement on  $\text{hA}_{2A}\text{AR}$ ), FSCPX (competition association on  $\text{hA}_1\text{AR}$ ), and LUF6632 (competition association on  $\text{hA}_{2A}\text{AR}$ ) was available as well from previous publications (Tables 3, 4, 5, and 6). Newly acquired radioligand binding data was from radioligand displacement assays with CPA, 8-CPT, and ZM-241,385 on the  $\text{hA}_1\text{AR}$ ; radioligand displacement assays with MSX-2 and DPCPX on the  $\text{hA}_{2A}\text{AR}$ ; and radioligand competition association assays with 8-CPT on the  $\text{hA}_1\text{AR}$  and with MSX-2 on the  $\text{hA}_{2A}\text{AR}$ .

MS binding saturation of the marker ligands DPCPX and ZM-241,385 to the  $\text{hA}_1\text{AR}$  and  $\text{hA}_{2A}\text{AR}$ , respectively, fitted a one-site saturation binding model (Fig. 3). DPCPX had an affinity of  $3.43\pm 0.02$  nM and a  $B_{\text{max}}$  of  $17.3\pm 0.3$  pmol/mg protein for the  $\text{hA}_1\text{AR}$  which was well in accordance with the previously found data from radioligand binding assays of  $2.5\pm 0.1$  nM and  $14\pm 1$  pmol/mg protein, respectively (Table 2). The same was true for ZM-241,385 with an MS binding affinity of  $1.03\pm 0.07$  nM and  $B_{\text{max}}$  of  $2.3\pm 0.3$  pmol/mg protein for the  $\text{hA}_{2A}\text{AR}$ , compared to a radioligand binding affinity of  $0.60\pm 0.07$  nM and  $B_{\text{max}}$  of  $1.9\pm 0.4$  pmol/mg protein. The displacement of marker ligands DPCPX and ZM-241,385 binding from the  $\text{hA}_1\text{AR}$  and  $\text{hA}_{2A}\text{AR}$  by their competing ligands fitted well to either one-state or two-state ligand binding displacement models (Fig. 4). The affinities found in MS



**Fig. 6** Competition association of DPCPX on  $\text{hA}_1\text{AR}$  in the presence or absence of 250 nM 8-CPT and 250 nM FSCPX (a), and of ZM-241,385 on  $\text{hA}_{2A}\text{AR}$  in the presence or absence of 90 nM MSX-2 and 15 nM

LUF6632 (b). Graphs show mean values of one representative MS binding competition association experiment performed in duplicate

**Table 2** Affinity and  $B_{\max}$  values of DPCPX for the  $hA_1AR$  and ZM-241,385 for the  $hA_{2A}AR$  as determined in MS binding and radioligand binding saturation assays. Values are mean  $K_D$  in nM $\pm$ SEM and mean  $B_{\max}$  in pmol/mg protein $\pm$ SEM of at least three independent experiments performed in duplicate

	$K_D \pm \text{SEM}$ (nM)		$B_{\max}$ (pmol/mg protein)	
	MS binding	Radioligand binding	MS binding	Radioligand binding
DPCPX on $hA_1AR$	3.43 $\pm$ 0.02	2.5 $\pm$ 0.1 [29]	17.3 $\pm$ 0.3	14 $\pm$ 1 [29]
ZM-241,385 on $hA_{2A}AR$	1.03 $\pm$ 0.07	0.60 $\pm$ 0.07 [23]	2.3 $\pm$ 0.3	1.9 $\pm$ 0.4 [23]

binding displacement assays for the competing ligands CPA, 8-CPT, ZM-241,385, and NECA for the  $hA_1AR$  (Table 3) and UK-432,097, MSX-2, DPCPX, and NECA for the  $hA_{2A}AR$  (Table 4) were in good agreement to the radioligand binding assays. The two-state binding model fits observed for the agonists CPA and NECA on the  $hA_1AR$  were observed in radioligand binding assays as well, and the resulting high and low affinity values were in good agreement (Table 3). The association and dissociation of marker ligands DPCPX and ZM-241,385 to the  $hA_1AR$  and  $hA_{2A}AR$  fitted well to one-phase association and dissociation models (Fig. 5), and the resulting association and dissociation rates were in good agreement between MS binding and radioligand binding assays (Tables 5 and 6).

With the association and dissociation rates validated for the marker ligands, MS binding competition association assays were performed. The competition association curves in the presence of FSCPX ( $hA_1AR$ ) and LUF6632 ( $hA_{2A}AR$ ) yielded an “overshoot” shape typical for slowly dissociating ligands, while in the presence of 8-CPT ( $hA_1AR$ ) and MSX-2 ( $hA_{2A}AR$ ), the curves were typical for fast-dissociating ligands (Fig. 6). FSCPX displaced the marker ligand DPCPX completely after 120 min. The association rates of 8-CPT and

MSX-2 agreed well between MS binding and radioligand binding assays, but less so in case of FSCPX and LUF6632 (Tables 5 and 6). The dissociation rates of 8-CPT, MSX-2, and LUF6632 were in good agreement as well, but not the apparent dissociation rate of FSCPX.

Linear regression performed on the correlation plots of MS binding data (based on M/IS detection) against radioligand binding data yielded the following coefficients of determination and equations:  $R^2=0.985$  and  $y=1.04x-0.199$  ( $K_i$  and  $K_D$ , Fig. 7a),  $R^2=0.775$  and  $y=0.738x+2.09$  ( $k_{on}$ , Fig. 7c), and  $R^2=0.968$  and  $y=1.06x-0.0550$  ( $k_{off}$ , Fig. 7e). Similar correlation plots of MS binding data without IS compensation, solely based on marker peak area, against radioligand binding data yielded  $R^2=0.988$  and  $y=1.05x-0.299$  ( $K_i$  and  $K_D$ , Fig. 7b),  $R^2=0.735$  and  $y=0.767x+1.82$  ( $k_{on}$ , Fig. 7d), and  $R^2=0.940$  and  $y=1.33x-0.0168$  ( $k_{off}$ , Fig. 7f).

## Discussion

### Preparation of internal standards

Including an internal or external standard is a good practice in mass spectrometry, to compensate for ion suppression by matrix effects from cell contents, sample evaporation, and instrumental drift [10]. We used the internal standard method as this is the most accurate manner to compensate for these sources of signal distortion and to increase the accuracy of MS methods.

**Table 3** Affinity ( $K_i$  values) of CPA, 8-CPT, ZM-241,385, and NECA as determined in MS binding and radioligand binding displacement assays on  $hA_1AR$ . The displacement curves of CPA and NECA fitted to a two-state site binding model, which yielded high and low binding affinities for the receptor. Values are mean  $K_i$  in nM $\pm$ SEM of at least three independent experiments performed in duplicate

	$K_i \pm \text{SEM}$ (nM)	
	MS binding	Radioligand binding
CPA	139 $\pm$ 32	175 $\pm$ 13
CPA-high	1.2 $\pm$ 0.4	1.0 $\pm$ 0.5
CPA-low	256 $\pm$ 81	304 $\pm$ 23
8-CPT	43 $\pm$ 11	31 $\pm$ 1
ZM-241,385	619 $\pm$ 78	523 $\pm$ 13
NECA	616 $\pm$ 76	731 $\pm$ 94 [22]
NECA-high	4.1 $\pm$ 1.4	4 $\pm$ 1 [22]
NECA-low	1273 $\pm$ 56	731 $\pm$ 94 [22]

**Table 4** Affinity ( $K_i$  values) of UK-432,097, MSX-2, DPCPX, and NECA as determined in MS binding and radioligand binding displacement assays on  $hA_{2A}AR$ . Values are mean  $K_i$  in nM $\pm$ SEM of at least three independent experiments performed in duplicate

	$K_i \pm \text{SEM}$ (nM)	
	MS binding	Radioligand binding
UK-432,097	52 $\pm$ 1	22 $\pm$ 5 [23]
MSX-2	9.0 $\pm$ 0.3	5.7 $\pm$ 0.1
DPCPX	550 $\pm$ 141	667 $\pm$ 77
NECA	100 $\pm$ 12	64 $\pm$ 1 [23]

**Table 5** Association and dissociation rates of DPCPX, 8-CPT, and FSCPX determined in MS binding and radioligand binding assays on the hA<sub>1</sub>AR. MS binding (M/IS) values were obtained by analysis with compensation by internal standard, just as the MS binding values in Tables 2, 3, and 4. MS binding (marker) values were obtained by analysis of marker chromatograms solely, without compensation by internal

standard, and thus label-free. The kinetic values of DPCPX were determined by association and dissociation assays, while the kinetic values of 8-CPT and FSCPX were determined by competition association assays with 6 nM DPCPX as marker ligand. Values are mean  $k_{\text{on}}$  in  $\text{M}^{-1} \text{min}^{-1} \pm \text{SEM}$  and mean  $k_{\text{off}}$  in  $\text{min}^{-1}$  of at least three independent experiments performed in duplicate

	$k_{\text{on}} \pm \text{SEM} (\text{M}^{-1} \text{min}^{-1})$			$k_{\text{off}} \pm \text{SEM} (\text{min}^{-1})$		
	MS binding (M/IS)	Radioligand binding	MS binding (marker)	MS binding (M/IS)	Radioligand binding	MS binding (marker)
DPCPX	$2.0 \pm 0.3 \times 10^8$	$1.4 \pm 0.2 \times 10^8$ [29]	$1.7 \pm 0.4 \times 10^8$	$0.29 \pm 0.02$	$0.25 \pm 0.01$ [29]	$0.31 \pm 0.02$
8-CPT	$5 \pm 2 \times 10^7$	$6 \pm 2 \times 10^7$	$3 \pm 2 \times 10^7$	$1.4 \pm 0.5$	$1.1 \pm 0.3$	$1.2 \pm 0.8$
FSCPX <sup>a</sup>	$0.7 \pm 0.2 \times 10^6$	$3.7 \pm 1.0 \times 10^6$ [29]	$0.7 \pm 0.2 \times 10^6$	$0.004 \pm 0.002$	$0.0010 \pm 0.0002$ [29]	$0.006 \pm 0.004$

<sup>a</sup> Apparent kinetic values were calculated for covalently binding FSCPX

Preferably, the internal standard is a molecule with the same chemical properties as the molecule of interest but with a distinct mass. Hence, deuterated DPCPX (d4) and ZM-241,385 (d4) were synthesized to serve as internal standard for the MS binding assays on hA<sub>1</sub>AR and hA<sub>2A</sub>AR, respectively. The resulting mass difference between the parent compounds and their internal standards ensured minimal signal overlap by their isotope patterns. For the synthesis of [<sup>2</sup>H<sub>4</sub>]ZM-241,385 5, the pure isotopologue [<sup>2</sup>H<sub>4</sub>]tyrosine (SI 14) was commercially available as precursor for the [<sup>2</sup>H<sub>4</sub>]tyramine 4 building block. For the synthesis of [<sup>2</sup>H<sub>4</sub>]DPCPX 2, the building block 1 was deuterated in-house by a rhodium-catalyzed reduction of two allylic double bonds in the presence of deuterium gas generated in situ. During this process, deuterium-hydrogen scrambling occurred which resulted in a mixture of isotopologues [<sup>2</sup>H<sub>0</sub>]DPCPX to [<sup>2</sup>H<sub>8</sub>]DPCPX in a Gaussian distribution as a final product. This had no negative influence on the results of the MS Binding assays, since the masses of parent ions and fragments of the most abundant isotopologue [<sup>2</sup>H<sub>4</sub>]DPCPX 5 were selected for quantification.

## MS binding assays

Affinity, association, and dissociation rates measured directly for the marker ligands DPCPX on the hA<sub>1</sub>AR and ZM-241,

385 on the hA<sub>2A</sub>AR were in good agreement to the values found in radioligand binding assays (Figs. 3 and 5, Tables 2, 5, and 6). The good performance of the MS binding saturation, association, and dissociation assays in which solely the marker ligand and no competing ligand was present was a prerequisite to continue with the MS binding displacement and competition association assays.

To demonstrate the MS binding displacement assays, a combination of selective and non-selective agonists and antagonists were chosen as competing ligands. For the hA<sub>1</sub>AR, these ligands were CPA, 8-CPT, ZM-241,385, and NECA, and for the hA<sub>2A</sub>AR, they were UK-432,097, MSX-2, DPCPX, and NECA. The determined affinity values were in good agreement between MS binding and radioligand binding assays for all these competing ligands (Fig. 4, Tables 3 and 4). Furthermore, the binding of agonists CPA and NECA to the hA<sub>1</sub>AR fitted to a pronounced two-phase displacement curve as was found before in radioligand binding assays.


Kinetic properties of ligands are of emerging interest and are thought to be important predictors of clinical performance [3, 26]. Therefore, we developed and validated MS binding competition association assays, by which kinetic properties of competing ligands can be analyzed by measuring the amount of bound marker ligand at different time points, in the presence of one concentration of these competing ligands. A fast

**Table 6** Association and dissociation rates of ZM-241,385, MSX-2, and LUF6632 determined in MS binding and radioligand binding assays on the hA<sub>2A</sub>AR. MS binding (M/IS) values were obtained by analysis with compensation by internal standard, just as the MS binding values in Tables 2, 3, and 4. MS binding (marker) values were obtained by analysis of marker chromatograms solely, without compensation by

internal standard, and thus label-free. The kinetic values of ZM-241,385 were determined by association and dissociation assays, while the kinetic values of MSX-2 and LUF6632 were determined by competition association assays with 3 nM ZM-241,385 as marker ligand. Values are mean  $k_{\text{on}}$  in  $\text{M}^{-1} \text{min}^{-1} \pm \text{SEM}$  and mean  $k_{\text{off}}$  in  $\text{min}^{-1}$  of at least three independent experiments performed in duplicate

	$k_{\text{on}} \pm \text{SEM} (\text{M}^{-1} \text{min}^{-1})$			$k_{\text{off}} \pm \text{SEM} (\text{min}^{-1})$		
	MS binding (M/IS)	Radioligand binding	MS binding (marker)	MS binding (M/IS)	Radioligand binding	MS binding (marker)
ZM-241,385	$9.5 \pm 0.7 \times 10^7$	$13 \pm 6 \times 10^7$ [14]	$9.8 \pm 2.0 \times 10^7$	$0.019 \pm 0.002$	$0.014 \pm 0.003$ [14]	$0.021 \pm 0.005$
MSX-2	$5.4 \pm 0.6 \times 10^6$	$2.4 \pm 0.2 \times 10^6$	$9.3 \pm 1.3 \times 10^6$	$0.027 \pm 0.005$	$0.026 \pm 0.004$	$0.063 \pm 0.022$
LUF6632	$0.7 \pm 0.1 \times 10^7$	$3.4 \pm 0.4 \times 10^7$ [14]	$1.8 \pm 0.7 \times 10^7$	$0.0028 \pm 0.0001$	$0.0031 \pm 0.0002$ [14]	$0.030 \pm 0.011$

**Fig. 7** Correlation plots of results obtained by MS binding and radioligand binding assays on hA<sub>1</sub>AR and hA<sub>2A</sub>AR. Values of marker ligands DPCPX and ZM-241,385 were measured directly on their respective binding targets hA<sub>1</sub>AR and hA<sub>2A</sub>AR by saturation (a, b), association (c, d), and dissociation (e, f) assays, while values of the competing ligands were measured indirectly by displacement (a, b) and competition association assays (c–f). Affinity values in pK<sub>D</sub> and pK<sub>i</sub> (a, b), association rates in k<sub>on</sub> (c, d), and dissociation rates in log k<sub>off</sub> (e, f) were compared. Correlation plots a, c, and e show MS binding results standardized with deuterium-labeled internal standard, while b, d, and f show truly label-free MS binding results without internal standard. Data points represent mean values of at least three separate experiments performed in duplicate. R<sup>2</sup> values were calculated by linear regression performed on log-transformed values



and a slowly dissociating competing ligand were chosen for each target. Fast- and slow-dissociating ligands yield distinct characteristic competition association graphs, without and with overshoot, respectively. For the hA<sub>1</sub>AR, the ligands 8-CPT and FSCPX and for hA<sub>2A</sub>AR, MSX-2 and LUF6632 were tested. 8-CPT and MSX-2 dissociate fast from their targets. FSCPX is an irreversibly binding antagonist selective for the hA<sub>1</sub>R [13, 27, 28] and thus yields the characteristic overshoot graph for slowly dissociating ligands [29], with the exception that it eventually displaces the marker ligand DPCPX

completely (Fig. 6a). LUF6632 was characterized earlier as a slowly dissociating ligand selective for the hA<sub>2A</sub>AR [14].

Dissociation rates were in good agreement between the MS binding and radioligand binding competition association assays (Fig. 7e, Tables 5 and 6), with the exception of the apparent dissociation rate of the irreversibly binding FSCPX (Table 5). Association rates found for the competing ligands in competition association assays varied more, especially for the slowly or not at all dissociating ligands FSCPX and LUF6632 (Fig. 7c, Tables 5 and 6). It has to be noted that as

it binds irreversibly to the hA<sub>1</sub>AR, FSCPX does not actually dissociate from the target. However, fitting the FSCPX data into the competition association model still enables the calculation of apparent association and dissociation rates. Being apparent values, they may vary between studies which could be an explanation for the diverging kinetic rates of FSCPX found in MS binding and radioligand binding assays (Table 5).

Altogether, these results validate the use of MS binding assays to determine affinity values and dissociation rates by saturation, association, dissociation, and competition association assays. However, association rate determination was only accurate by direct measurement on the marker ligands.

### Necessity of deuterium-labeled internal standard

As mentioned above, including an internal or external standard is a good practice in mass spectrometry. We used the internal standard method as this is the most accurate manner to compensate for sources of signal distortion. However, the use of a deuterium-labeled internal standard makes the MS binding assay a labeled assay, even if the marker ligand that binds to the target is itself unlabeled. For fast screening of new marker ligands, the use of an external standard or even no standard at all would be vastly advantageous, as the whole assay becomes an unlabeled assay. Moreover, to directly determine association and dissociation rates of non-labeled ligands would be an improvement over the use of competition association assays. Therefore, we compared the performance of the MS binding assay with and without compensation by deuterium-labeled internal standard. Although in the latter case the resulting graphs of each separate experiment were somewhat less accurate,  $K_i$  and  $K_D$  values could still be determined without loss of accuracy (Fig. 7b). The  $k_{off}$  values indirectly determined by the competition association assay correlated less well with radioligand binding assays, although retaining a good coefficient of determination (Fig. 7f). The determination of  $k_{on}$  values correlated less well with radioligand binding assays irrespective of the use of an internal standard (Fig. 7c, d). In contrast to this, the directly measured association and dissociation rates of marker ligands DPCPX and ZM-241,385 were still in good agreement with radioligand binding experiments (Tables 5 and 6).

### Conclusion

We developed and validated MS binding assays for the adenosine A<sub>1</sub> and A<sub>2A</sub> receptors. The results from ligand saturation, association, dissociation, and displacement assays were in good agreement with radioligand binding data. The results from competition association assays were in good agreement with radioligand binding data for dissociation rates but less so

for association rates. Furthermore, we investigated the necessity to include deuterium-labeled internal standards in MS binding assays. Saturation, association, dissociation, and displacement assay results were still in good agreement with radioligand binding assays when the internal standard was not included. In competition association assays, the inclusion of an internal standard was beneficial for good correlation of dissociation rates with radioligand binding data. However, by excluding the use of internal standards in MS binding assays, it would be relatively simple to measure association and dissociation rates of a number of unlabeled ligands directly, without the need for competition association assays. We conclude that the use of deuterium-labeled internal standards is in this case unnecessary which makes the MS binding assay a truly unlabeled ligand binding assay. As this internal standard-free approach may be applied to other targets than the currently investigated adenosine A<sub>1</sub> and A<sub>2A</sub> receptors, we foresee the promising future application of MS binding to directly measure binding properties by saturation, association, and dissociation assays, without the use of any labeled internal standards.

**Acknowledgments** We kindly thank Dr. G. Höfner and Prof. K. T. Wanner (Ludwig Maximilians University, München, Germany) for their advice on MS binding assays and J. C. Schoeman (LACDR, Leiden University, The Netherlands) for his advice on triple quadrupole MS handling. MSX-2 and UK-432,097 were kind gifts from Prof. C. E. Müller (Bonn University, Germany) and Pfizer's Compound Transfer Program, respectively. This work was supported by the Netherlands Organization for Scientific Research—Chemical Sciences (Grant 714.011.001).

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

### References

1. Hulme EC, Trevethick MA (2010) Ligand binding assays at equilibrium: validation and interpretation. *Br J Pharmacol* 161(6):1219–1237. doi:10.1111/j.1476-5381.2009.00604.x
2. Lohse MJ, Nuber S, Hoffmann C (2012) Fluorescence/bioluminescence resonance energy transfer techniques to study G-protein-coupled receptor activation and signaling. *Pharmacol Rev* 64(2):299–336. doi:10.1124/pr.110.004309
3. Hoffmann C, Castro M, Rinken A, Leurs R, Hill SJ, Vischer HF (2015) Ligand residence time at G-protein-coupled receptors—why we should take our time to study it. *Mol Pharmacol* 88(3):552–560. doi:10.1124/mol.115.099671
4. Grimm SH, Höfner G, Wanner KT (2015) MS binding assays for the three monoamine transporters using the triple reuptake inhibitor (1R,3S)-indatraline as native marker. *ChemMedChem* 10(6):1027–1039. doi:10.1002/cmdc.201500084

5. Hess M, Höfner G, Wanner KT (2011) Development and validation of a rapid LC-ESI-MS/MS method for quantification of fluoxetine and its application to MS binding assays. *Anal Bioanal Chem* 400(10):3505–3515. doi:10.1007/s00216-011-4997-0
6. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Mu CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. *63* (1):1–34. doi:10.1124/pr.110.003285.1
7. Chen JF, Eltzschig HK, Fredholm BB (2013) Adenosine receptors as drug targets—what are the challenges? *Nat Rev Drug Discov* 12(4):265–286. doi:10.1038/nrd3955
8. Lohse MJ, Klotz KN, Lindenborn-Fotinos J, Reddington M, Schwabe U, Olsson RA (1987) 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)—a selective high affinity antagonist radioligand for A<sub>1</sub> adenosine receptors. *Naunyn Schmiedeberg's Arch Pharmacol* 336(2):204–210
9. Alexander SPH, Millns PJ (2001) [<sup>3</sup>H]ZM241385—an antagonist radioligand for adenosine A<sub>2A</sub> receptors in rat brain. *Eur J Pharmacol* 411(3):205–210
10. Mulvana DE (2010) Critical topics in ensuring data quality in bioanalytical LC-MS method development. *Bioanalysis* 2(6):1051–1072. doi:10.4155/bio.10.60
11. Botitsi HV, Garbis SD, Economou A, Tsipi DF (2011) Current mass spectrometry strategies for the analysis of pesticides and their metabolites in food and water matrices. *Mass Spectrom Rev* 30(5):907–939. doi:10.1002/mas.20307
12. Müller CE, Maurinsh J, Sauer R (2000) Binding of [<sup>3</sup>H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes—a new, selective antagonist radioligand for A<sub>2A</sub> adenosine receptors. *Eur J Pharm Sci* 10(4):259–265
13. Van Muijlwijk-Koezen JE, Timmerman H, Van der Sluis RP, Van de Stolpe AC, Menge WM, Beukers MW, Van der Graaf PH, De Groot M, IJzerman AP (2001) Synthesis and use of FSCPX, an irreversible adenosine A<sub>1</sub> antagonist, as a 'receptor knock-down' tool. *Bioorg Med Chem Lett* 11(6):815–818
14. Guo D, Xia L, Van Veldhoven JP, Hazeu M, Mocking T, Brussee J, IJzerman AP, Heitman LH (2014) Binding kinetics of ZM241385 derivatives at the human adenosine A<sub>2A</sub> receptor. *ChemMedChem* 9(4):752–761. doi:10.1002/cmcd.201300474
15. Devi I, Bhuyan PJ (2005) An expedient method for the synthesis of 6-substituted uracils under microwave irradiation in a solvent-free medium. *Tetrahedron Lett* 46(34):5727–5729. doi:10.1016/j.tetlet.2005.06.075
16. Soriano A, Ventura R, Molero A, Hoen R, Casadó V, Cortés A, Fanelli F, Albericio F, Lluís C, Franco R, Royo M (2009) Adenosine A<sub>2A</sub> receptor-antagonist/dopamine D<sub>2</sub> receptor-agonist bivalent ligands as pharmacological tools to detect A<sub>2A</sub>-D<sub>2</sub> receptor heteromers. *J Med Chem* 52(18):5590–5602. doi:10.1021/jm900298c
17. Erickson RH, Hiner RN, Feeney SW, Blake PR, Rzeszutowski WJ, Hicks RP, Costello DG, Abreu ME (1991) 1,3,8-Trisubstituted xanthines. Effects of substitution pattern upon adenosine receptor A<sub>1</sub>/A<sub>2</sub> affinity. *J Med Chem* 34(4):1431–1435
18. Jörg M, Agostino M, Yuriev E, Mak F, Miller N, White J, Scammells P, Capuano B (2013) Synthesis, molecular structure, NMR spectroscopic and computational analysis of a selective adenosine A<sub>2A</sub> antagonist, ZM 241385. *Struct Chem* 24(4):1241–1251. doi:10.1007/s11224-012-0151-7
19. Jörg M, Shonberg J, Mak FS, Miller ND, Yuriev E, Scammells PJ, Capuano B (2013) Novel adenosine A<sub>2A</sub> receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A<sub>2A</sub> receptor antagonists for extending into extracellular space. *Bioorg Med Chem Lett* 23(11):3427–3433. doi:10.1016/j.bmcl.2013.03.070
20. Ntai I, Phelan VV, Bachmann BO (2006) Phosphonopeptide K-26 biosynthetic intermediates in *Astrosporangium hypotensionis*. *Chem Commun (Camb)* 43:4518–4520
21. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC, Anal B (1985) Measurement of protein using bicinchoninic acid. *Anal Biochem* 150(1):76–85
22. Guo D, Venhorst SN, Massink A, Van Veldhoven JP, Vauquelin G, IJzerman AP, Heitman LH (2014) Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A<sub>1</sub> adenosine receptor. *Br J Pharmacol* 171(23):5295–5312. doi:10.1111/bph.12836
23. Guo D, Mulder-Krieger T, IJzerman AP, Heitman LH (2012) Functional efficacy of adenosine A<sub>2A</sub> receptor agonists is positively correlated to their receptor residence time. *Br J Pharmacol* 166(6):1846–1859. doi:10.1111/j.1476-5381.2012.01897.x
24. Motulsky HJ, Mahan LC (1984) The kinetics of competitive radioligand binding predicted by the law of mass action. *Mol Pharmacol* 25(1):1–9
25. Adair GRA, Kapoor KK, Scolan ALB, Williams JMJ (2006) Ruthenium catalysed reduction of alkenes using sodium borohydride. *Tetrahedron Lett* 47(50):8943–8944. doi:10.1016/j.tetlet.2006.10.026
26. Guo D, Hillger JM, IJzerman AP, Heitman LH (2014) Drug-target residence time—a case for G protein-coupled receptors. *Med Res Rev* 34(4):856–892. doi:10.1002/med.21307
27. Scammells PJ, Baker SP, Belardinelli L, Olsson RA (1994) Substituted 1,3-dipropylxanthines as irreversible antagonists of A<sub>1</sub> adenosine receptors. *J Med Chem* 37(17):2704–2712
28. Srinivas M, Shryock JC, Scammells PJ, Ruble J, Baker SP, Belardinelli L (1996) A novel irreversible antagonist of the A<sub>1</sub>-adenosine receptor. *Mol Pharmacol* 50(1):196–205
29. Guo D, Van Dorp EJ, Mulder-Krieger T, Van Veldhoven JP, Brussee J, IJzerman AP, Heitman LH (2013) Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics. *J Biomol Screen* 18(3):309–320. doi:10.1177/1087057112464776